An FDA advisory committee meets today to discuss whether to give emergency approval to a COVID-19 vaccine developed by Moderna. Assistant Dean for Translational Research at LSU Health New Orleans School of Medicine, Doctor Lucio Miele says the data looks remarkably good.
“As good as what we saw last week from Pfizer.”
The Moderna vaccine could receive FDA approval soon. An advisory panel of the FDA is meeting today looking at Moderna’s trial results. Miele says the data looks remarkably good and the side effects are minor.
“Soreness, chills, aches, sometimes fever but the real adverse effects were really not a concern.”
Miele says the efficacy rate for the Moderna vaccine is 94-percent.
“Over 94 percent of individuals who received the vaccine when they have been infected have not developed symptomatic illnesses.”
Comments